Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

ohm, sorry to hijack this thread but thought you m

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153773
(Total Views: 513)
Posted On: 05/10/2020 10:15:59 PM
Posted By: thriftycents
Re: ohm20 #33258
ohm, sorry to hijack this thread but thought you might be able to answer this question that I have seen posted as your knowledge of how to interpret these medical papers seems to be immense :-)

Regarding the Kawasaki Disease symptoms seen in these children in NY, is it possible that this is related to the fact that this is a RANTES disease?

https://journals.plos.org/plosone/article?id=...ne.0011458

notes

Quote:
The CCL3L1-CCR5 axis may play an important role in KD pathogenesis. In addition to clinical and laboratory parameters, genetic markers may also predict risk of CAL and resistance to IVIG.



and

Quote:
here is evidence to suggest that recruitment of inflammatory cells in KD may be mediated through CC chemokine receptor 5 (CCR5) [15], [19], [26]. Chemotactic gradients for homing of CCR5+ cells are provided by a variety of chemokines, the most potent of which is its ligand - CC ligand 3 like 1 (CCL3L1) [27]. The genes encoding CCR5 and CCL3L1 demonstrate two distinct types of polymorphisms: single nucleotide polymorphisms in CCR5 [28] and copy number variation (CNV) in the CCL3L1-gene containing segmental duplication [29]. There is a growing interest in understanding the contribution of CNV in disease pathogenesis since it is recognized that 12% of the human genome may have undergone segmental duplications [30], [31]. We previously found that variations in CCR5 and CCL3L1 affect susceptibility to KD in parent-child trios from the United States [15].



from my elementary understanding, it seems like if what this paper is stating is true, that KD could be a potential manifestation of this being a RANTES disease and leronlimab may stop the progression of the disease to KD given that it occupies CCR5

is that a fair hypothesis?

TIA


(1)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us